This week, the Biden administration rescinded a Trump administration-proposed plan that would have allowed Medicare Part D plans to limit coverage of some drugs in each of the “six protected classes.” The Trump policy sought to remove the protected classes and allow coverage of only one drug per class, including certain cancer treatments. NCCS has long opposed changes to the six protected classes.
Cancer patients often require combination therapy, as well as a range of different drugs over the course of their treatment. Eliminating the six protected classes policy would deny patients access to necessary medications. We are pleased that the Biden administration is listening to patient groups and other stakeholders, and rescinding this harmful policy.
Read our letter with the Cancer Leadership Council (CLC):